Oluwamisimi Abib (M.D) @misimiabib - Twitter Profile

https://t.co/y1oLVNGdRU Our team is delighted to share our recently published article: “Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction” in the American Journal of Cardiovascular Drugs. Drawing from 138 references, we synthesized evidence, proposing frameworks and nuances to consider. Key highlights include: ✅ Practical considerations for ezetimibe, PCSK9 mabs/inclisiran, bempedoic acid, quoting pivotal trials, observational and pragmatic studies, and safety data to support these considerations ✅ Emerging therapies like CETP inhibitors, agents that target APO C-III, APO A-1, APO-B, and ANGPTL3, as well as CRISPR technology and inflammation-modulating agents. Coupled with a brief overview of lipid trafficking mechanisms to better understand these agents ✅ The concept of Residual Cardiovascular risk and how it plays into future research directions for ASCVD risk reduction, e.g Ziltivekimab etc ✅ Cost-effectiveness of these agents and integration of ICER in practical decision-making. ✅ Adherence, statin-intolerance/ drucebo effect, and patient preference challenges in real-world lipid management This work reflects the contributions of a multi-institutional team spanning the U.S., U.K., and internationally, bringing together academic and clinical perspectives. 🔗 Access the article via Springer Nature’s SharedIt link: https://t.co/cgcmDa628D We are grateful to our mentors and collaborators for making this ambitious project possible. We hope this serves as a useful resource for clinicians, researchers, and policymakers.

dr_arkad's tweet photo. https://t.co/y1oLVNGdRU
Our team is delighted to share our recently published article:
“Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction” in the American Journal of Cardiovascular Drugs.
Drawing from 138 references, we synthesized evidence, proposing frameworks and nuances to consider. Key highlights include:
✅ Practical considerations for ezetimibe, PCSK9 mabs/inclisiran, bempedoic acid, quoting pivotal trials, observational and pragmatic studies, and safety data to support these considerations
✅ Emerging therapies like CETP inhibitors, agents that target APO C-III, APO A-1, APO-B, and ANGPTL3, as well as CRISPR technology and inflammation-modulating agents. Coupled with a brief overview of lipid trafficking mechanisms to better understand these agents
✅ The concept of Residual Cardiovascular risk and how it plays into future research directions for ASCVD risk reduction, e.g Ziltivekimab etc
✅ Cost-effectiveness of these agents and integration of ICER in practical decision-making.
✅ Adherence, statin-intolerance/ drucebo effect, and patient preference challenges in real-world lipid management

This work reflects the contributions of a multi-institutional team spanning the U.S., U.K., and internationally, bringing together academic and clinical perspectives.

🔗 Access the article via Springer Nature’s SharedIt link: https://t.co/cgcmDa628D

We are grateful to our mentors and collaborators for making this ambitious project possible. We hope this serves as a useful resource for clinicians, researchers, and policymakers.

1

69

17

9

6K

Oluwamisimi Abib (M.D) @misimiabib

about 1 year ago

@ProjectImg @Intealth My PD!!!🙌🏾🙌🏾🙌🏾

0

1

0

178

misimiabib retweeted

Kayode Ogunniyi MD, MRCP(UK) @dr_arkad

about 1 year ago

Our team is pleased to share that our manuscript has been accepted and is now in production at the American Journal of Cardiovascular Drugs. This work offers a practical, educational, and forward-looking overview of established and emerging non-statin lipid-lowering therapies, with direct reference to key clinical trials and supporting evidence. Stay tuned